Estonia -
estone -
Ravimiamet
cefuroxime venus pharma süste-/infusioonilahuse pulber
venus pharma gmbh - tsefuroksiim - süste-/infusioonilahuse pulber - 750mg 1tk
Estonia -
estone -
Ravimiamet
cefuroxime venus pharma süste-/infusioonilahuse pulber
venus pharma gmbh - tsefuroksiim - süste-/infusioonilahuse pulber - 1,5g 1tk
Estonia -
estone -
Ravimiamet
ceftriaxone venus pharma süste-/infusioonilahuse pulber
venus pharma gmbh - tseftriaksoon - süste-/infusioonilahuse pulber - 2g 10tk; 2g 1tk; 2g 5tk
Estonia -
estone -
Ravimiamet
ceftriaxone venus pharma süste-/infusioonilahuse pulber
venus pharma gmbh - tseftriaksoon - süste-/infusioonilahuse pulber - 1g 1tk; 1g 10tk
Estonia -
estone -
Ravimiamet
hechocur pekana pillid
pekana naturheilmittel gmbh - homöopaatilised preparaadid - pillid - 10g 1tk
Estonia -
estone -
Ravimiamet
itires pekana pillid
pekana naturheilmittel gmbh - homöopaatilised preparaadid - pillid - 10g 1tk
Estonia -
estone -
Ravimiamet
difoss pekana pillid
pekana naturheilmittel gmbh - homöopaatilised preparaadid - pillid - 10g 1tk
Estonia -
estone -
Ravimiamet
infragil pekana pillid
pekana naturheilmittel gmbh - homöopaatilised preparaadid - pillid - 10g 1tk
Estonia -
estone -
Ravimiamet
otidolo pekana kõrvatilgad, lahus
pekana naturheilmittel gmbh - homöopaatilised preparaadid - kõrvatilgad, lahus - 10ml 1tk
Unione Europea -
estone -
EMA (European Medicines Agency)
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - mitu müeloomit - antineoplastilised ained - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.